Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-Label, Multicenter Pivotal Study to Evaluate the Safety and Efficacy of GelrinC® for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle: A Comparison to Historical Control Microfracture

NCT03262909 is registered in ClinicalTrials.gov with Regentis Biomaterials as lead sponsor.

NCT NCT03262909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03262909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-Label, Multicenter Pivotal Study to Evaluate the Safety and Efficacy of GelrinC® for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle: A Comparison to Historical Control Microfracture
Lead sponsor
Regentis Biomaterials
Phase
Not applicable
Overall status
Unknown status
Start date
November 14, 2017
Completion date
November 30, 2024
Enrollment
181 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

articular cartilage defects in the knee joint